We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Blood Biomarker Predicts Guillain-Barré Prognosis

By LabMedica International staff writers
Posted on 25 Nov 2020
Guillain-Barré syndrome (GBS) is a rare, autoimmune disorder in which a person’s own immune system damages the nerves, causing muscle weakness and sometimes paralysis. More...
GBS can cause symptoms that last for a few weeks to several years. Most people recover fully, but some have permanent nerve damage.

The diagnosis of GBS depends on findings such as rapid development of muscle paralysis, absent reflexes, absence of fever, and absence of a likely cause. Cerebrospinal fluid analysis (through a lumbar spinal puncture) and nerve conduction studies are supportive investigations commonly performed in the diagnosis of GBS. Testing for antiganglioside antibodies is often performed, but their contribution to diagnosis is usually limited.

A team of neurologists and their colleagues associated with the Hospital de la Santa Creu i Sant Pau (Barcelona, Spain) measured serum neurofilament light chain (sNfL) in 98 samples and 24 cerebrospinal fluid (CSF) samples of GBS patients using single-molecule array technology, comparing them with samples from 53 age-matched healthy controls.

GBS patients were an average age of 57, and 57.1% were men. Most (68.4%) presented with GBS symptoms after an infectious event; median time from symptom onset to inclusion in the study was four days. Two-thirds of patients presented with the typical sensorimotor variant of GBS. Most patients were treated with intravenous immunoglobulin (77.6%) or intravenous immunoglobulin plus plasma exchange (10.2%).

The scientists reported that at baseline, median sNfL levels were five times higher for GBS patients than controls (55.49 pg/mL versus 9.83 pg/mL) and CSF levels were also higher (1,308.5 pg/mL versus 440.24 pg/mL). GBS patients with preceding diarrhea had higher sNfL levels than patients with respiratory symptoms or those who had no preceding infection (134.90 pg/mL versus 47.86 pg/mL versus 38.02 pg/mL), respectively. Patients with pure motor GBS variant and Miller Fisher syndrome showed higher sNfL levels than patients with typical GBS (162.18 pg/mL versus 95.50 pg/mL versus 38.02 pg/mL). Patients with acute motor axonal neuropathy (AMAN) had higher serum sNfL levels than other variants (199.53 pg/mL versus 46.77 pg/mL).

Luis Querol, MD, PhD, a Neurologist and co-author of the study, said, “These findings are important on several levels. First, they confirm that residual long-term disability in GBS is clearly associated to the degree of axonal damage that happens at the onset of the disease. They also suggest that sNfL could be used to stratify patients at admission, and in the future, select patients who may be candidates for more aggressive therapies or those who may have good prognosis independently of the apparent severity they have at onset.”

The authors concluded that baseline sNfL levels are increased in patients with GBS, are associated with disease severity and axonal variants and have an independent prognostic value in patients with GBS. The study was published on November 5, 2020 in the Journal of Neurology, Neurosurgery, and Psychiatry.

Related Links:
Hospital de la Santa Creu i Sant Pau


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
Varicella Zoster Virus Assay
LIAISON VZV Assay Panel (IgG HT, IgM)
New
Francisella Tularensis Test
TULAREMIA VIRCLIA IgG+IgM MONOTEST
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: New biomarkers could someday make it easy to spot Parkinson’s disease in a patient’s blood sample (Photo courtesy of Shutterstock)

Unique Blood-Based Genetic Signature Can Diagnose Parkinson’s Disease

Parkinson's disease is primarily recognized for its impact on the central nervous system. Recent scientific progress has shifted focus to understanding the involvement of the immune system in the onset... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Technology

view channel
Image: Concept of biosensor integrated into hygiene pads enabling direct semi-quantitative analysis of biomarkers in unprocessed menstruation blood (Photo courtesy of Dosnon, L et al. DOI: 10.1002/advs.202505170)

First Ever Technology Recognizes Disease Biomarkers Directly in Menstrual Blood in Sanitary Towels

Over 1.8 billion people menstruate worldwide, yet menstrual blood has been largely overlooked in medical practice. This blood contains hundreds of proteins, many of which correlate with their concentration... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.